A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies
Authors
Sharp, A.Williams, A.
Blagden, S. P.
Plummer, E. R.
Hochhauser, D.
Krebs, Matthew G
Pacey, S.
Evans, T. R. J.
Whelan, S.
Nandakumar, S.
Rogers, S.
Jameson, K. L.
Basile, F. G.
De Bono, J. S.
Arkenau, H. T.
Affiliation
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, SuttonIssue Date
2022
Metadata
Show full item recordCitation
Sharp A, Williams A, Blagden SP, Plummer ER, Hochhauser D, Krebs M, et al. A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304856.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS2691Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS2691